Crystal Structures of the Human SUMO-2 Protein at 1.6 A and 1.2 A Resolution: Implication on the Functional Differences of SUMO Proteins
Overview
Affiliations
The SUMO proteins are a class of small ubiquitin-like modifiers. SUMO is attached to a specific lysine side chain on the target protein via an isopeptide bond with its C-terminal glycine. There are at least four SUMO proteins in humans, which are involved in protein trafficking and targeting. A truncated human SUMO-2 protein that contains residues 9-93 was expressed in Escherichia coli and crystallized in two different unit cells, with dimensions of a=b=75.25 A, c=29.17 A and a=b=74.96 A, c=33.23 A, both belonging to the rhombohedral space group R3. They diffracted X-rays to 1.6 A and 1.2 A resolution, respectively. The structures were determined by molecular replacement using the yeast SMT3 protein as a search model. Subsequent refinements yielded R/Rfree values of 0.169/0.190 and 0.119/0.185, at 1.6 A and 1.2 A, respectively. The peptide folding of SUMO-2 consists of a half-open beta-barrel and two flanking alpha-helices with secondary structural elements arranged as betabetaalphabetabetaalphabeta in the sequence, identical to those of ubiquitin, SMT3 and SUMO-1. Comparison of SUMO-2 with SUMO-1 showed a surface region near the C terminus with significantly different charge distributions. This may explain their distinct intracellular locations. In addition, crystal-packing analysis suggests a possible trimeric assembly of the SUMO-2 protein, of which the biological significance remains to be determined.
Auto-sumoylation of the Ubc9 E2 SUMO-conjugating Enzyme Extends Cellular Lifespan.
Ryu H, Jeong D, Kim S, Jeoung S, Zhao D, Knight J Res Sq. 2024; .
PMID: 38562857 PMC: 10984013. DOI: 10.21203/rs.3.rs-4016606/v1.
The role of SUMOylation in the neurovascular dysfunction after acquired brain injury.
Luo P, Li L, Huang J, Mao D, Lou S, Ruan J Front Pharmacol. 2023; 14:1125662.
PMID: 37033632 PMC: 10073463. DOI: 10.3389/fphar.2023.1125662.
SUMO pathway is required for ribosome biogenesis.
Ryu H BMB Rep. 2022; 55(11):535-540.
PMID: 36195568 PMC: 9712707.
SUMOylation targeting mitophagy in cardiovascular diseases.
Xiao H, Zhou H, Zeng G, Mao Z, Zeng J, Gao A J Mol Med (Berl). 2022; 100(11):1511-1538.
PMID: 36163375 DOI: 10.1007/s00109-022-02258-4.
Krajewski W Front Genet. 2022; 13:873398.
PMID: 35571051 PMC: 9096104. DOI: 10.3389/fgene.2022.873398.